Kidney disease biomarker
View Patent ↗The disclosure provides methods and solid states devices for detecting and staging chronic kidney disease in a patient, where the levels of biomarkers in a sample obtained from a patient are elevated or reduced compared to the levels in a sample obtained from healthy subject. In addition, the disclosure provides the use of methods and solid state devices for measurement of specific biological markers for determining the efficacy of a treatment for chronic kidney disease and for determining a drug treatment protocol for a subject suffering from chronic kidney disease.
1. A method for detecting kidney disease, comprising
obtaining a serum, blood or plasma sample from a subject;
contacting the serum, blood or plasma sample with a solid support having immobilized thereon a plurality of antibodies that specifically bind to the biomarkers complement C3a (des) Arg (C3a desArg), macrophage inflammatory protein 1 alpha (MIP1α) and optionally any of the biomarkers selected from group (a) or group (b) consisting of:
(a) Interleukin-8 (IL-8), adiponectin (ADPN), dipeptidyl peptidase 4 (CD26), c-reactive protein (CRP), cystatin c (CYSC), D-dimer, endothelial growth factor (EGF), e-selectin (ESEL), granulocyte-macrophage colony stimulating factor (GMCSF), intercellular adhesion molecule 1 (ICAM1), interferon gamma (IFNγ), interleukin 10 (IL10), interleukin 15 (IL15), interleukin 1β(IL1β), interleukin 5 (IL5), interleukin 6 (IL6), liver fatty acid binding protein (LFABP), monocyte chemotactic protein 1 (MCP1), matrix metalloproteinase 9 (MMP9), neutrophil gelatinase-associated lipocalin (NGAL), p selectin (PSEL), soluble interleukin 2 alpha (sIL2α), soluble tumour necrosis factor receptor 2 (STNFR2), soluble tumour necrosis factor 1 (STNFR1), tumour necrosis factor alpha (TNFα), vascular endothelial growth factor (VEGF), vascular cell adhesion molecule 1 (VCAM1), and any combination thereof;
(b) creatinine, interleukin-4 (IL4), L-selectin (LSEL), neuron specific enolase (NSE), interleukin 1α (IL1α), and
measuring the binding of said biomarkers to the antibodies on the solid support, wherein if C3a desArg and MIP1α are increased in the sample with respect to a normal control value, and optionally whether one or more biomarker from group (a) are increased and one or more biomarkers from group (b) are decreased with respect to a normal control value is indicative of kidney disease.
2. A method according to claim 1 , wherein the kidney disease is stage 1, stage 2 or stage 3 chronic kidney disease.
3. A method according to claim 1 , wherein the sample is plasma or serum.
4. A method according to claim 1 , wherein the plurality of antibodies are detectably-labelled.
5. A method according to claim 4 , wherein the detectable label is horse-radish peroxidase.
6. A method according to claim 1 , wherein the solid support is a biochip.
7. A method according to claim 6 , wherein the amount of a biomarker in the sample is measured using a sandwich ELISA assay.
8. A method according to claim 1 , wherein the levels of C3a desArg, CYSC and MIP1α are measured.
9. A method according to claim 1 , wherein the levels of C3a desArg, GMCSF, CYSC and MIP1α are measured.
10. A method according to claim 1 , wherein the levels of C3a desArg, TNFA, CYSC and MIP1α are measured.
11. A method according to claim 1 , wherein the levels of C3a desArg, CRP, CYSC, EGF, FABP1, IL8, sTNFR1, sTNFR2, D-dimer, NGAL and MIP1α are measured.